The aim is to assess how effective and safe pimavanserin is for treating psychosis in Parkinson’s disease.
Conducted a meta-analysis of placebo-controlled randomized controlled trials.
Evaluated multiple studies focusing on pimavanserin and its impact on Parkinson’s disease psychosis.
Included trials assessing efficacy and safety outcomes.
Pimavanserin significantly reduced psychotic symptoms in patients compared to placebo.
Safety profile was consistent with previous studies, with no new safety concerns identified.
Abstract
To evaluate the efficacy and safety of pimavanserin in Parkinson’s disease psychosis (PDP) through a meta-analysis of placebo-controlled randomized controlled trials (RCTs).